Idelalisib, ibrutinib show benefits in CLL.

challenging in general, not only for children’s cancers,” says Chesler. “To encourage commercial development, the EMA should consider creative and more robust ways of working with pharma, academia, and government to make the PIP scheme more effi cient.” The FDA and the EMA already share information and communicate regularly about promising drugs, says Reaman. “It’s possible for the FDA and the EMA to require studies that may be different but complementary to increase the amount of useful information available,” he says. ■